Case Report
Copyright ©The Author(s) 2025.
World J Clin Oncol. Feb 24, 2025; 16(2): 98812
Published online Feb 24, 2025. doi: 10.5306/wjco.v16.i2.98812
Figure 1
Figure 1 Pathological examination and immunostaining of programmed cell death protein ligand 1. A: Programmed cell death protein ligand 1 in tumor proportion score; B: Programmed cell death protein ligand 1 in combined positive score; C: Positive control; D: Negative control.
Figure 2
Figure 2  Computed tomography scans of the patient.